nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ALB—chronic obstructive pulmonary disease	0.17	1	CbGaD
Mirabegron—Arbutamine—Formoterol—chronic obstructive pulmonary disease	0.145	0.306	CrCrCtD
Mirabegron—Arbutamine—Arformoterol—chronic obstructive pulmonary disease	0.145	0.306	CrCrCtD
Mirabegron—Labetalol—Formoterol—chronic obstructive pulmonary disease	0.0918	0.194	CrCrCtD
Mirabegron—Labetalol—Arformoterol—chronic obstructive pulmonary disease	0.0918	0.194	CrCrCtD
Mirabegron—SLCO1A2—Prednisolone—chronic obstructive pulmonary disease	0.0385	0.158	CbGbCtD
Mirabegron—SLCO1A2—Prednisone—chronic obstructive pulmonary disease	0.0363	0.149	CbGbCtD
Mirabegron—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.022	0.0906	CbGbCtD
Mirabegron—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.022	0.0906	CbGbCtD
Mirabegron—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0196	0.0808	CbGbCtD
Mirabegron—ALB—Prednisone—chronic obstructive pulmonary disease	0.0188	0.0772	CbGbCtD
Mirabegron—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0185	0.076	CbGbCtD
Mirabegron—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0125	0.0514	CbGbCtD
Mirabegron—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0119	0.049	CbGbCtD
Mirabegron—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0106	0.0437	CbGbCtD
Mirabegron—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0104	0.0428	CbGbCtD
Mirabegron—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00982	0.0404	CbGbCtD
Mirabegron—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00623	0.0256	CbGbCtD
Mirabegron—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00588	0.0242	CbGbCtD
Mirabegron—BCHE—diaphragm—chronic obstructive pulmonary disease	0.0014	0.476	CbGeAlD
Mirabegron—Arbutamine—ADRB2—chronic obstructive pulmonary disease	0.000891	0.463	CrCbGaD
Mirabegron—Labetalol—ADRB2—chronic obstructive pulmonary disease	0.000632	0.329	CrCbGaD
Mirabegron—ADRB3—connective tissue—chronic obstructive pulmonary disease	0.000489	0.166	CbGeAlD
Mirabegron—Atrial fibrillation—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.0046	CcSEcCtD
Mirabegron—Palpitations—Roflumilast—chronic obstructive pulmonary disease	0.000432	0.00457	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.000413	0.00437	CcSEcCtD
Mirabegron—Atrial fibrillation—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00434	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Tiotropium—chronic obstructive pulmonary disease	0.00041	0.00434	CcSEcCtD
Mirabegron—Glaucoma—Prednisolone—chronic obstructive pulmonary disease	0.000408	0.00432	CcSEcCtD
Mirabegron—Propafenone—CYP1A2—chronic obstructive pulmonary disease	0.000399	0.208	CrCbGaD
Mirabegron—Infection—Roflumilast—chronic obstructive pulmonary disease	0.000396	0.00419	CcSEcCtD
Mirabegron—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000388	0.0041	CcSEcCtD
Mirabegron—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.000383	0.00404	CcSEcCtD
Mirabegron—Sinusitis—Tiotropium—chronic obstructive pulmonary disease	0.000369	0.0039	CcSEcCtD
Mirabegron—Nasopharyngitis—Formoterol—chronic obstructive pulmonary disease	0.000369	0.0039	CcSEcCtD
Mirabegron—Nasopharyngitis—Arformoterol—chronic obstructive pulmonary disease	0.000369	0.0039	CcSEcCtD
Mirabegron—Gastritis—Arformoterol—chronic obstructive pulmonary disease	0.000365	0.00386	CcSEcCtD
Mirabegron—Gastritis—Formoterol—chronic obstructive pulmonary disease	0.000365	0.00386	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000364	0.00384	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.000363	0.00384	CcSEcCtD
Mirabegron—Nasopharyngitis—Montelukast—chronic obstructive pulmonary disease	0.000361	0.00382	CcSEcCtD
Mirabegron—Influenza—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.00377	CcSEcCtD
Mirabegron—Influenza—Formoterol—chronic obstructive pulmonary disease	0.000356	0.00377	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.000356	0.00376	CcSEcCtD
Mirabegron—Rhinitis—Tiotropium—chronic obstructive pulmonary disease	0.000354	0.00374	CcSEcCtD
Mirabegron—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.000351	0.00371	CcSEcCtD
Mirabegron—Influenza—Montelukast—chronic obstructive pulmonary disease	0.000349	0.00369	CcSEcCtD
Mirabegron—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.000349	0.00369	CcSEcCtD
Mirabegron—Nasopharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.00368	CcSEcCtD
Mirabegron—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.000347	0.00367	CcSEcCtD
Mirabegron—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.000346	0.00366	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000345	0.00364	CcSEcCtD
Mirabegron—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000344	0.00364	CcSEcCtD
Mirabegron—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000341	0.00361	CcSEcCtD
Mirabegron—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.000339	0.00358	CcSEcCtD
Mirabegron—Influenza—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00356	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Formoterol—chronic obstructive pulmonary disease	0.000331	0.0035	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000331	0.0035	CcSEcCtD
Mirabegron—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.00033	0.00349	CcSEcCtD
Mirabegron—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.000326	0.00345	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Montelukast—chronic obstructive pulmonary disease	0.000324	0.00343	CcSEcCtD
Mirabegron—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000317	0.00335	CcSEcCtD
Mirabegron—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000315	0.00334	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000313	0.00331	CcSEcCtD
Mirabegron—Infestation—Montelukast—chronic obstructive pulmonary disease	0.000311	0.00329	CcSEcCtD
Mirabegron—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.000311	0.00329	CcSEcCtD
Mirabegron—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000309	0.00326	CcSEcCtD
Mirabegron—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000309	0.00326	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.000308	0.00326	CcSEcCtD
Mirabegron—Sinusitis—Formoterol—chronic obstructive pulmonary disease	0.000298	0.00315	CcSEcCtD
Mirabegron—Sinusitis—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.00315	CcSEcCtD
Mirabegron—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.000297	0.00315	CcSEcCtD
Mirabegron—Glaucoma—Prednisone—chronic obstructive pulmonary disease	0.000297	0.00314	CcSEcCtD
Mirabegron—Sinusitis—Montelukast—chronic obstructive pulmonary disease	0.000292	0.00309	CcSEcCtD
Mirabegron—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000291	0.00308	CcSEcCtD
Mirabegron—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00029	0.00306	CcSEcCtD
Mirabegron—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.000288	0.00305	CcSEcCtD
Mirabegron—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000286	0.00303	CcSEcCtD
Mirabegron—Rhinitis—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00302	CcSEcCtD
Mirabegron—Rhinitis—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00302	CcSEcCtD
Mirabegron—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000282	0.00298	CcSEcCtD
Mirabegron—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000282	0.00298	CcSEcCtD
Mirabegron—Sinusitis—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00297	CcSEcCtD
Mirabegron—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00296	CcSEcCtD
Mirabegron—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00296	CcSEcCtD
Mirabegron—Rhinitis—Montelukast—chronic obstructive pulmonary disease	0.00028	0.00296	CcSEcCtD
Mirabegron—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00296	CcSEcCtD
Mirabegron—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00296	CcSEcCtD
Mirabegron—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000276	0.00292	CcSEcCtD
Mirabegron—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000274	0.0029	CcSEcCtD
Mirabegron—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00289	CcSEcCtD
Mirabegron—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000273	0.00289	CcSEcCtD
Mirabegron—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000272	0.00287	CcSEcCtD
Mirabegron—Rhinitis—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.00285	CcSEcCtD
Mirabegron—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000266	0.00281	CcSEcCtD
Mirabegron—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000266	0.00281	CcSEcCtD
Mirabegron—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.0028	CcSEcCtD
Mirabegron—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000265	0.0028	CcSEcCtD
Mirabegron—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.0028	CcSEcCtD
Mirabegron—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000264	0.0028	CcSEcCtD
Mirabegron—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00279	CcSEcCtD
Mirabegron—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000264	0.00279	CcSEcCtD
Mirabegron—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00279	CcSEcCtD
Mirabegron—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000262	0.00277	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00026	0.00275	CcSEcCtD
Mirabegron—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00026	0.00275	CcSEcCtD
Mirabegron—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000259	0.00274	CcSEcCtD
Mirabegron—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000256	0.00271	CcSEcCtD
Mirabegron—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000252	0.00266	CcSEcCtD
Mirabegron—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000251	0.00266	CcSEcCtD
Mirabegron—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00025	0.00264	CcSEcCtD
Mirabegron—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00264	CcSEcCtD
Mirabegron—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000249	0.00264	CcSEcCtD
Mirabegron—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000245	0.00259	CcSEcCtD
Mirabegron—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000244	0.00258	CcSEcCtD
Mirabegron—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00254	CcSEcCtD
Mirabegron—Back pain—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00254	CcSEcCtD
Mirabegron—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000237	0.00251	CcSEcCtD
Mirabegron—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000234	0.00248	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000229	0.00242	CcSEcCtD
Mirabegron—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.0024	CcSEcCtD
Mirabegron—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000223	0.00236	CcSEcCtD
Mirabegron—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00234	CcSEcCtD
Mirabegron—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.00232	CcSEcCtD
Mirabegron—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000219	0.00232	CcSEcCtD
Mirabegron—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000218	0.0023	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000217	0.00229	CcSEcCtD
Mirabegron—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000215	0.00227	CcSEcCtD
Mirabegron—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00227	CcSEcCtD
Mirabegron—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000214	0.00227	CcSEcCtD
Mirabegron—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.00227	CcSEcCtD
Mirabegron—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00224	CcSEcCtD
Mirabegron—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.00223	CcSEcCtD
Mirabegron—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000211	0.00223	CcSEcCtD
Mirabegron—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00021	0.00222	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00021	0.00222	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.00222	CcSEcCtD
Mirabegron—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00219	CcSEcCtD
Mirabegron—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00219	CcSEcCtD
Mirabegron—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00219	CcSEcCtD
Mirabegron—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00219	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000206	0.00217	CcSEcCtD
Mirabegron—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000205	0.00217	CcSEcCtD
Mirabegron—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00214	CcSEcCtD
Mirabegron—Infection—Formoterol—chronic obstructive pulmonary disease	0.000201	0.00213	CcSEcCtD
Mirabegron—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.00213	CcSEcCtD
Mirabegron—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00211	CcSEcCtD
Mirabegron—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.00211	CcSEcCtD
Mirabegron—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000198	0.0021	CcSEcCtD
Mirabegron—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000198	0.00209	CcSEcCtD
Mirabegron—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.00209	CcSEcCtD
Mirabegron—Infection—Montelukast—chronic obstructive pulmonary disease	0.000197	0.00208	CcSEcCtD
Mirabegron—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00208	CcSEcCtD
Mirabegron—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00208	CcSEcCtD
Mirabegron—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00206	CcSEcCtD
Mirabegron—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000194	0.00205	CcSEcCtD
Mirabegron—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00204	CcSEcCtD
Mirabegron—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00201	CcSEcCtD
Mirabegron—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000188	0.00199	CcSEcCtD
Mirabegron—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00197	CcSEcCtD
Mirabegron—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00196	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.00195	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000185	0.00195	CcSEcCtD
Mirabegron—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000182	0.00193	CcSEcCtD
Mirabegron—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000181	0.00192	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000181	0.00191	CcSEcCtD
Mirabegron—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00189	CcSEcCtD
Mirabegron—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00189	CcSEcCtD
Mirabegron—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000178	0.00188	CcSEcCtD
Mirabegron—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000176	0.00186	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00185	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00185	CcSEcCtD
Mirabegron—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00185	CcSEcCtD
Mirabegron—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00185	CcSEcCtD
Mirabegron—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00185	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.00184	CcSEcCtD
Mirabegron—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00183	CcSEcCtD
Mirabegron—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00183	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00181	CcSEcCtD
Mirabegron—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00181	CcSEcCtD
Mirabegron—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00178	CcSEcCtD
Mirabegron—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000168	0.00178	CcSEcCtD
Mirabegron—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000168	0.00177	CcSEcCtD
Mirabegron—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000168	0.00177	CcSEcCtD
Mirabegron—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000167	0.00176	CcSEcCtD
Mirabegron—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000166	0.00175	CcSEcCtD
Mirabegron—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000166	0.00175	CcSEcCtD
Mirabegron—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000166	0.00175	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00175	CcSEcCtD
Mirabegron—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00174	CcSEcCtD
Mirabegron—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00173	CcSEcCtD
Mirabegron—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000162	0.00172	CcSEcCtD
Mirabegron—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000162	0.00171	CcSEcCtD
Mirabegron—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000161	0.0017	CcSEcCtD
Mirabegron—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.0017	CcSEcCtD
Mirabegron—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00016	0.00169	CcSEcCtD
Mirabegron—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00016	0.00169	CcSEcCtD
Mirabegron—BCHE—respiratory system—chronic obstructive pulmonary disease	0.00016	0.0543	CbGeAlD
Mirabegron—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000158	0.00167	CcSEcCtD
Mirabegron—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000158	0.00167	CcSEcCtD
Mirabegron—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000158	0.00167	CcSEcCtD
Mirabegron—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000158	0.00167	CcSEcCtD
Mirabegron—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000157	0.00166	CcSEcCtD
Mirabegron—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00166	CcSEcCtD
Mirabegron—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00165	CcSEcCtD
Mirabegron—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00161	CcSEcCtD
Mirabegron—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.0016	CcSEcCtD
Mirabegron—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000149	0.00158	CcSEcCtD
Mirabegron—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.00154	CcSEcCtD
Mirabegron—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000145	0.00154	CcSEcCtD
Mirabegron—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000143	0.00152	CcSEcCtD
Mirabegron—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000143	0.00152	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00151	CcSEcCtD
Mirabegron—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000142	0.00151	CcSEcCtD
Mirabegron—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00149	CcSEcCtD
Mirabegron—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00014	0.00148	CcSEcCtD
Mirabegron—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.00147	CcSEcCtD
Mirabegron—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000139	0.00147	CcSEcCtD
Mirabegron—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.00145	CcSEcCtD
Mirabegron—ORM1—lung—chronic obstructive pulmonary disease	0.000137	0.0465	CbGeAlD
Mirabegron—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000136	0.00144	CcSEcCtD
Mirabegron—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.00143	CcSEcCtD
Mirabegron—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.00142	CcSEcCtD
Mirabegron—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000134	0.00142	CcSEcCtD
Mirabegron—BCHE—bronchus—chronic obstructive pulmonary disease	0.000131	0.0447	CbGeAlD
Mirabegron—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000131	0.00139	CcSEcCtD
Mirabegron—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.00138	CcSEcCtD
Mirabegron—BCHE—smooth muscle tissue—chronic obstructive pulmonary disease	0.000129	0.0437	CbGeAlD
Mirabegron—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.00135	CcSEcCtD
Mirabegron—Rash—Formoterol—chronic obstructive pulmonary disease	0.000128	0.00135	CcSEcCtD
Mirabegron—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.00135	CcSEcCtD
Mirabegron—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000128	0.00135	CcSEcCtD
Mirabegron—Headache—Formoterol—chronic obstructive pulmonary disease	0.000127	0.00134	CcSEcCtD
Mirabegron—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000127	0.00134	CcSEcCtD
Mirabegron—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.00134	CcSEcCtD
Mirabegron—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.00134	CcSEcCtD
Mirabegron—Rash—Montelukast—chronic obstructive pulmonary disease	0.000125	0.00132	CcSEcCtD
Mirabegron—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000125	0.00132	CcSEcCtD
Mirabegron—Headache—Montelukast—chronic obstructive pulmonary disease	0.000124	0.00131	CcSEcCtD
Mirabegron—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00128	CcSEcCtD
Mirabegron—SLCO1A2—lung—chronic obstructive pulmonary disease	0.000121	0.041	CbGeAlD
Mirabegron—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.00127	CcSEcCtD
Mirabegron—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.00127	CcSEcCtD
Mirabegron—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00012	0.00127	CcSEcCtD
Mirabegron—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.00127	CcSEcCtD
Mirabegron—BCHE—trachea—chronic obstructive pulmonary disease	0.000118	0.0401	CbGeAlD
Mirabegron—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000118	0.00125	CcSEcCtD
Mirabegron—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.00123	CcSEcCtD
Mirabegron—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.0012	CcSEcCtD
Mirabegron—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00117	CcSEcCtD
Mirabegron—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.00113	CcSEcCtD
Mirabegron—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000105	0.00111	CcSEcCtD
Mirabegron—Vision blurred—Prednisone—chronic obstructive pulmonary disease	9.2e-05	0.000973	CcSEcCtD
Mirabegron—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.71e-05	0.000921	CcSEcCtD
Mirabegron—BCHE—lung—chronic obstructive pulmonary disease	8.48e-05	0.0288	CbGeAlD
Mirabegron—Hypertension—Prednisone—chronic obstructive pulmonary disease	8.43e-05	0.000892	CcSEcCtD
Mirabegron—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.32e-05	0.000879	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.26e-05	0.000873	CcSEcCtD
Mirabegron—Infection—Prednisone—chronic obstructive pulmonary disease	7.92e-05	0.000837	CcSEcCtD
Mirabegron—Tachycardia—Prednisone—chronic obstructive pulmonary disease	7.78e-05	0.000823	CcSEcCtD
Mirabegron—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.74e-05	0.000819	CcSEcCtD
Mirabegron—ABCB1—respiratory system—chronic obstructive pulmonary disease	7.61e-05	0.0259	CbGeAlD
Mirabegron—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.26e-05	0.000768	CcSEcCtD
Mirabegron—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.25e-05	0.000767	CcSEcCtD
Mirabegron—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000742	CcSEcCtD
Mirabegron—Rash—Prednisolone—chronic obstructive pulmonary disease	6.92e-05	0.000731	CcSEcCtD
Mirabegron—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.91e-05	0.000731	CcSEcCtD
Mirabegron—Fatigue—Prednisone—chronic obstructive pulmonary disease	6.87e-05	0.000727	CcSEcCtD
Mirabegron—Headache—Prednisolone—chronic obstructive pulmonary disease	6.87e-05	0.000727	CcSEcCtD
Mirabegron—Constipation—Prednisone—chronic obstructive pulmonary disease	6.82e-05	0.000721	CcSEcCtD
Mirabegron—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.52e-05	0.000689	CcSEcCtD
Mirabegron—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.52e-05	0.000689	CcSEcCtD
Mirabegron—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.00067	CcSEcCtD
Mirabegron—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.3e-05	0.000666	CcSEcCtD
Mirabegron—BCHE—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	6.03e-05	0.00412	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	5.92e-05	0.00404	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.75e-05	0.00393	CbGpPWpGaD
Mirabegron—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.72e-05	0.000605	CcSEcCtD
Mirabegron—ALB—Vitamin B12 Metabolism—CRP—chronic obstructive pulmonary disease	5.66e-05	0.00387	CbGpPWpGaD
Mirabegron—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.64e-05	0.000596	CcSEcCtD
Mirabegron—ABCB1—trachea—chronic obstructive pulmonary disease	5.62e-05	0.0191	CbGeAlD
Mirabegron—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.45e-05	0.000577	CcSEcCtD
Mirabegron—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.27e-05	0.000557	CcSEcCtD
Mirabegron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	5.17e-05	0.00353	CbGpPWpGaD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	5.15e-05	0.00352	CbGpPWpGaD
Mirabegron—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	5.15e-05	0.00352	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—MUC5AC—chronic obstructive pulmonary disease	5.13e-05	0.0035	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	5.09e-05	0.00347	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	5.07e-05	0.00346	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.05e-05	0.00345	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	5.04e-05	0.00344	CbGpPWpGaD
Mirabegron—Rash—Prednisone—chronic obstructive pulmonary disease	5.03e-05	0.000531	CcSEcCtD
Mirabegron—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.02e-05	0.000531	CcSEcCtD
Mirabegron—Headache—Prednisone—chronic obstructive pulmonary disease	4.99e-05	0.000528	CcSEcCtD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	4.86e-05	0.00332	CbGpPWpGaD
Mirabegron—Nausea—Prednisone—chronic obstructive pulmonary disease	4.73e-05	0.000501	CcSEcCtD
Mirabegron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	4.63e-05	0.00316	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	4.63e-05	0.00316	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—CRP—chronic obstructive pulmonary disease	4.61e-05	0.00315	CbGpPWpGaD
Mirabegron—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	4.57e-05	0.00312	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	4.53e-05	0.0031	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.53e-05	0.0031	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	4.46e-05	0.00304	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—MUC1—chronic obstructive pulmonary disease	4.36e-05	0.00298	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—SERPINE1—chronic obstructive pulmonary disease	4.35e-05	0.00297	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	4.32e-05	0.00295	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	4.26e-05	0.00291	CbGpPWpGaD
Mirabegron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	4.17e-05	0.00285	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	4.16e-05	0.00284	CbGpPWpGaD
Mirabegron—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	4.11e-05	0.00281	CbGpPWpGaD
Mirabegron—ABCB1—lung—chronic obstructive pulmonary disease	4.04e-05	0.0137	CbGeAlD
Mirabegron—SLCO1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.98e-05	0.00272	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	3.97e-05	0.00271	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	3.97e-05	0.00271	CbGpPWpGaD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	3.95e-05	0.0027	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.92e-05	0.00268	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.86e-05	0.00264	CbGpPWpGaD
Mirabegron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.75e-05	0.00256	CbGpPWpGaD
Mirabegron—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	3.74e-05	0.00256	CbGpPWpGaD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	3.68e-05	0.00251	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	3.66e-05	0.0025	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	3.63e-05	0.00248	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—SERPINE1—chronic obstructive pulmonary disease	3.54e-05	0.00242	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	3.54e-05	0.00242	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—IL1B—chronic obstructive pulmonary disease	3.53e-05	0.00241	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—APIP—chronic obstructive pulmonary disease	3.49e-05	0.00238	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.48e-05	0.00238	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.45e-05	0.00236	CbGpPWpGaD
Mirabegron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	3.38e-05	0.00231	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.3e-05	0.00225	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.26e-05	0.00223	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	3.17e-05	0.00217	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.16e-05	0.00216	CbGpPWpGaD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	3.1e-05	0.00212	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	3.07e-05	0.00209	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.06e-05	0.00209	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—SERPINE1—chronic obstructive pulmonary disease	3.03e-05	0.00207	CbGpPWpGaD
Mirabegron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	3.03e-05	0.00207	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.02e-05	0.00206	CbGpPWpGaD
Mirabegron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	2.99e-05	0.00204	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—chronic obstructive pulmonary disease	2.89e-05	0.00197	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	2.87e-05	0.00196	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.83e-05	0.00194	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	2.81e-05	0.00192	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.81e-05	0.00192	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.74e-05	0.00187	CbGpPWpGaD
Mirabegron—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.71e-05	0.00185	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.63e-05	0.0018	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.61e-05	0.00178	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—TNF—chronic obstructive pulmonary disease	2.56e-05	0.00175	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.56e-05	0.00175	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.49e-05	0.0017	CbGpPWpGaD
Mirabegron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	2.45e-05	0.00168	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.45e-05	0.00167	CbGpPWpGaD
Mirabegron—SLCO1A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	2.41e-05	0.00165	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.38e-05	0.00163	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.32e-05	0.00158	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.31e-05	0.00158	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.29e-05	0.00157	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.29e-05	0.00156	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	2.28e-05	0.00156	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	2.27e-05	0.00155	CbGpPWpGaD
Mirabegron—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.26e-05	0.00154	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GC—chronic obstructive pulmonary disease	2.25e-05	0.00154	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.18e-05	0.00149	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	2.18e-05	0.00149	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	2.16e-05	0.00147	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.13e-05	0.00146	CbGpPWpGaD
Mirabegron—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	2.13e-05	0.00146	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.1e-05	0.00144	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.09e-05	0.00143	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	2.09e-05	0.00143	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—TNF—chronic obstructive pulmonary disease	2.09e-05	0.00142	CbGpPWpGaD
Mirabegron—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.07e-05	0.00142	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	2.07e-05	0.00141	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.04e-05	0.0014	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—ACE—chronic obstructive pulmonary disease	2.01e-05	0.00137	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.99e-05	0.00136	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	1.99e-05	0.00136	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.98e-05	0.00135	CbGpPWpGaD
Mirabegron—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.97e-05	0.00134	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.95e-05	0.00133	CbGpPWpGaD
Mirabegron—ALB—Metabolism—APIP—chronic obstructive pulmonary disease	1.94e-05	0.00133	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	1.92e-05	0.00131	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.9e-05	0.0013	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.87e-05	0.00127	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.87e-05	0.00127	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	1.85e-05	0.00126	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—TP53—chronic obstructive pulmonary disease	1.84e-05	0.00126	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	1.82e-05	0.00125	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	1.82e-05	0.00124	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—PLAUR—chronic obstructive pulmonary disease	1.81e-05	0.00123	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	1.79e-05	0.00123	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.77e-05	0.00121	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	1.77e-05	0.00121	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.71e-05	0.00117	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	1.7e-05	0.00116	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	1.7e-05	0.00116	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	1.68e-05	0.00115	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.67e-05	0.00114	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	1.66e-05	0.00113	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	1.6e-05	0.0011	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	1.58e-05	0.00108	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	1.58e-05	0.00108	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.55e-05	0.00106	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.5e-05	0.00102	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.48e-05	0.00101	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	1.42e-05	0.000968	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.4e-05	0.000956	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.39e-05	0.000946	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.38e-05	0.000945	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.38e-05	0.000939	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.36e-05	0.000932	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.36e-05	0.000926	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	1.35e-05	0.000919	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.34e-05	0.000913	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.3e-05	0.00089	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—MMP1—chronic obstructive pulmonary disease	1.29e-05	0.000881	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.29e-05	0.000881	CbGpPWpGaD
Mirabegron—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.29e-05	0.000879	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.29e-05	0.000878	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.28e-05	0.000873	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.28e-05	0.000872	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.27e-05	0.000866	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.26e-05	0.000862	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GC—chronic obstructive pulmonary disease	1.25e-05	0.000855	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—LEP—chronic obstructive pulmonary disease	1.25e-05	0.000853	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.23e-05	0.000839	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.23e-05	0.000838	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GCLC—chronic obstructive pulmonary disease	1.21e-05	0.000829	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.17e-05	0.0008	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.16e-05	0.000795	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.16e-05	0.000794	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.13e-05	0.000773	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.13e-05	0.00077	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CTGF—chronic obstructive pulmonary disease	1.11e-05	0.000756	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.1e-05	0.000749	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.06e-05	0.000726	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.05e-05	0.00072	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.05e-05	0.000716	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.05e-05	0.000715	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.03e-05	0.000706	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.02e-05	0.000697	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.02e-05	0.000696	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	9.98e-06	0.000682	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.7e-06	0.000663	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.61e-06	0.000656	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.57e-06	0.000654	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.57e-06	0.000653	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.51e-06	0.00065	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.27e-06	0.000633	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	9.26e-06	0.000632	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.15e-06	0.000625	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	9.14e-06	0.000624	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	9.11e-06	0.000622	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	8.97e-06	0.000612	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.92e-06	0.000609	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.75e-06	0.000597	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.51e-06	0.000581	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.51e-06	0.000581	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	8.5e-06	0.00058	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.45e-06	0.000577	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.4e-06	0.000573	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	8.37e-06	0.000571	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—CXCL8—chronic obstructive pulmonary disease	8.3e-06	0.000567	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	8.24e-06	0.000563	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	8.2e-06	0.00056	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.82e-06	0.000534	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	7.81e-06	0.000533	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.42e-06	0.000506	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7e-06	0.000478	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.95e-06	0.000474	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	6.94e-06	0.000474	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	6.89e-06	0.00047	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.84e-06	0.000467	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	6.76e-06	0.000462	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	6.76e-06	0.000461	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.68e-06	0.000456	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	6.62e-06	0.000452	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.38e-06	0.000435	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.28e-06	0.000429	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	6.17e-06	0.000421	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.99e-06	0.000409	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.92e-06	0.000404	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ALB—chronic obstructive pulmonary disease	5.75e-06	0.000392	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.68e-06	0.000388	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.66e-06	0.000386	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.65e-06	0.000386	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	5.58e-06	0.000381	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	5.5e-06	0.000375	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	5.4e-06	0.000369	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.38e-06	0.000367	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.25e-06	0.000359	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.12e-06	0.000349	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	5.09e-06	0.000348	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ALB—chronic obstructive pulmonary disease	5.04e-06	0.000344	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.98e-06	0.00034	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—NOS3—chronic obstructive pulmonary disease	4.82e-06	0.000329	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	4.77e-06	0.000326	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.74e-06	0.000324	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.69e-06	0.00032	CbGpPWpGaD
Mirabegron—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.67e-06	0.000319	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.59e-06	0.000314	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	4.38e-06	0.000299	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.36e-06	0.000297	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.22e-06	0.000288	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.15e-06	0.000284	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.13e-06	0.000282	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.13e-06	0.000282	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.1e-06	0.00028	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.91e-06	0.000267	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.86e-06	0.000264	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.82e-06	0.000261	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.69e-06	0.000252	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.65e-06	0.000249	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.62e-06	0.000247	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	3.61e-06	0.000246	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.6e-06	0.000246	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.47e-06	0.000237	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.41e-06	0.000233	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.33e-06	0.000227	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.18e-06	0.000217	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.07e-06	0.00021	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	2.69e-06	0.000183	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.56e-06	0.000175	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.52e-06	0.000172	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.46e-06	0.000168	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.35e-06	0.000161	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.35e-06	0.000161	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.32e-06	0.000158	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.23e-06	0.000152	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.22e-06	0.000151	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.52e-06	0.000103	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.45e-06	9.9e-05	CbGpPWpGaD
